Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

  title={Ustekinumab induction and maintenance therapy in refractory Crohn's disease.},
  author={W J Sandborn and Christopher R Gasink and Long-Long Gao and Marion A. Blank and Jewel Johanns and C. Guzzo and Bruce E Sands and S B Hanauer and Stephan Raoul Targan and P. R. Rutgeerts and Subrata Ghosh and Willem J. S. de Villiers and Remo Panaccione and Gordon Greenberg and Stefan Schreiber and Simon Lichtiger and Brian G Feagan},
  journal={The New England journal of medicine},
  volume={367 16},
BACKGROUND In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown. METHODS We evaluated ustekinumab in adults with moderate-to-severe Crohn's disease that was resistant to anti-tumor necrosis factor (TNF) treatment. During induction, 526 patients were randomly assigned to receive intravenous ustekinumab (at a dose of 1, 3, or 6 mg per kilogram of body weight) or placebo at week 0. During the maintenance… CONTINUE READING
Highly Influential
This paper has highly influenced 17 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 40 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 280 extracted citations


Publications referenced by this paper.
Showing 1-10 of 24 references

Seminar : Crohn ’ s disease — etiology , immunobiology , diagnostic approach and evidence based management

  • D Baumgart, WJ Sandborn
  • Lancet
  • 2012

Similar Papers

Loading similar papers…